4.3 Review

Fertility, Contraception, and Novel Reproductive Technologies in Chronic Kidney Disease

Journal

SEMINARS IN NEPHROLOGY
Volume 37, Issue 4, Pages 327-336

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semnephrol.2017.05.004

Keywords

Chronic kidney disease; fertility; pregnancy; contraception; cyclophosphamide; ovarian reserve

Funding

  1. Alberta Innovates-Health Solutions
  2. Alberta Health and Wellness
  3. University of Calgary
  4. University of Alberta

Ask authors/readers for more resources

Chronic kidney disease (CKD) affects hypothalamic-pituitary-gonadal axis function, leading to menstrual abnormalities, sexual dysfunction, functional menopause, and loss of fertility. Pregnancy in a patient with CKD is associated with a higher risk of complications to both the mother and the fetus, highlighting the importance of contraceptive counseling at all stages of CKD. There has been limited research on the safety and efficacy of different contraceptive methods in the CKD population, and it is important to tailor the choice of contraception to the patient's lifestyle and comorbidity status. Cyclophosphamide is a commonly used immunosuppressive agent that impairs fertility in a dose-dependent fashion, with greater impact in older women of child-bearing age. Strategies to reduce the impact of cyclophosphamide on ovarian reserve as well as fertility preservation technologies are options to consider when treating immune-mediated CKD. A multidisciplinary approach in counseling the woman with CKD who wishes to contemplate or avoid pregnancy is necessary to optimize outcomes. Further research in this important area is required. (C) 2017 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available